Search
Showing results for "aboriginal respiratory"
14 important The Kids Research Institute Australia research projects have received support under the inaugural WA Near-miss Awards (WANMA) funding program.
The Kids Research Institute Australia researchers have been awarded five of eight State Government awards designed to help cover the hidden costs of conducting research.
Current NICE 2015 guidelines for bronchiolitis state that the use of HFNC is becoming widespread without demonstration of additional efficacy.
ATP Binding Cassette Subfamily A Member 3 (ABCA-3) is a lipid transporter protein highly expressed in type-II alveolar (AT-II) cells. Mutations in ABCA3 can result in severe respiratory disease in infants and children. To study ABCA-3 deficiency in vitro, primary AT-II cells would be the cell culture of choice although sample accessibility is limited. Our aim was to investigate the suitability of primary nasal epithelial cells, as a surrogate culture model for AT-II cells, to study ABCA-3 deficiency.
We aimed to explore whether newborns in high-risk areas have pre-existing pneumococcal-specific cellular immune responses that effects early acquisition.
Nasopharyngeal colonisation with nontypeable Haemophilus influenzae (NTHi) is associated with development of infections including pneumonia and otitis media. The 10-valent pneumococcal conjugate vaccine (PCV10) uses NTHi Protein D (PD) as a carrier. Papua New Guinean children have exceptionally early and dense NTHi carriage, and high rates of NTHi-associated disease.
The Ear and Hearing Health team's vision is all children start primary school with good hearing.
The Opportunity An opportunity for an experienced Research Officer to cover a period of Maternity Leave relief 2-3 days per week from February 2019
The Opportunity We are seeking a motivated Research Coordinator to coordinate clinical research studies being undertakne by the AREST CF team. The
Electronic cigarette use, especially among younger members of society, has grown to concerning levels in many countries, including Australia and New Zealand. Uptake in the general population, driven by technological and pharmacological innovations, and accelerated by aggressive tobacco/vaping industry marketing, has outpaced medical research.